linjc16/ctgov huggingface dataset:
An Observational Study of IgA Nephropathy: Pathological Variants and Clinical Data

Study Overview
=================
Brief Summary
-----------------
The pathological variants of IgA nephropathy identified by the Oxford classification may be related to the clinical data at presentation and follow-up, including proteinuria and renal function. This study is aimed to identify the potential relationship between pathological variants and clinical data in IgA nephropathy.

Official Title
-----------------
An Observational Study of the Relationship Between Pathological Variants and Clinical Data at Presentation and Follow-up in IgA Nephropathy

Conditions
-----------------
IgA Nephropathy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: biopsy-proven IgA nephropathy; Exclusion Criteria:

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| glomerular filtration rate decline or end-stage renal disease or doubling of serum creatinine |  | after the biopsy | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
IgA nephropathy
Branched Chain Aminoacid Supplementation in Patients With Liver Cirrhosis

Study Overview
=================
Brief Summary
-----------------
Malnutrition is a frequent complication in patients with liver cirrhosis. Most patients have decreased dietary intake due to ascites, hepatic encephalopathy and pro-inflammatory cytokines. We hypothesized that branched chain aminoacids can improve nutritional status and delay episodes of hepatic encephalopathy

Official Title
-----------------
High-fiber High-fiber Diet and Branched Chain Aminoacids. Impact on Nutritional Status and Complications in Patients With Liver Cirrhosis

Conditions
-----------------
Liver Cirrhosis

Intervention / Treatment
-----------------
* Dietary Supplement: Branched-chain aminoacids
* Other: High-fiber high protein diet


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ambulatory patients Patients with confirmed diagnose of liver cirrhosis Patients classified as Child-Pugh A or Child Pugh B Exclusion Criteria: Acute or chronic renal failure Pregnancy Overt hepatic encephalopathy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Diet plus branched chain aminoacids<br>High-fiber high-protein diet Oral supplement : branched chain aminoacids | Dietary Supplement: Branched-chain aminoacids<br> <br> Other: High-fiber high protein diet<br> <br> |
| Active Comparator: Diet<br>High-fiber high-protein diet | Other: High-fiber high protein diet<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Nutritional status | Assessed by bioelectrical impedance vector analysis and mid-arm muscle circumference | At time of recruitment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hepatic Encephalopathy |  | At time of recruitment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Branched chain aminoacids, Nutritional status, Hepatic encephalopathy
Comparative Study of Two Embryo Culture Systems

Study Overview
=================
Brief Summary
-----------------
The centre for Medically-Assisted Procreation (MAP) of Dijon CHU has two high-technology embryo culture systems, with incubation characteristics that are potentially superior to those provided by classical culture systems. Indeed, these two systems, available in only two MAP centres in France, make it possible to maintain a stable temperature and gaseous environment during the in-vitro development of the embryos. It is necessary to observe the development of the embryos to determine which embryos have the highest implantation potential. These observations are done from time to time by microscope for one system and continuously using an incorporated video camera for the other (cinematographic study). The MAP centre in Dijon wishes to compare the interest of these two systems.

Official Title
-----------------
Comparative Study of Two Embryo Culture Systems: Randomization of Attempts at In Vitro Fertilization With ICSI at the Centre for Medically Assisted Procreation at Dijon CHU

Conditions
-----------------
Infertility

Intervention / Treatment
-----------------
* Device: Embryoscope
* Device: Embryo culture system without incorporated camera


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Persons who have provided oral consent Attempt at In Vitro Fertilization with ICSI (IntraCytoplasmic Sperm Injection) At least 6 mature ovocytes to microinject Exclusion Criteria: Persons not covered by national health insurance Attempt at In Vitro Fertilization (IVF) Fewer than 6 mature ovocytes Decision to transfer at the zygote stage during the multidisciplinary meeting Attempts made in a context of viral risk (both systems are in a virus risk-free zone) Attempts with surgically-harvested spermatozoa

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Embryoscope group<br> | Device: Embryoscope<br> <br> |
| Embryo culture without incorporated camera group<br> | Device: Embryo culture system without incorporated camera<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Implantation rate | The implantation rate is defined as the number of embryos implanted (gestational sacs seen on the US scan) compared to the total number of embryos transferred. | 16 weeks after transfer | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of miscarriages |  | 16 weeks after transfer | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
In Vitro Fertilization with ICSI
Periodontal Osseous Wall Piezosplitting and EDTA Root Surface Etching

Study Overview
=================
Brief Summary
-----------------
This study was designed to investigate the use of minimally invasive Piezo knife to harvest vascularized interceptal bone pedicle in treating intrabony defects.

Detailed Description
-----------------
Sixteen non-smoking patients with severe chronic periodontitis participated in this prospective, randomized clinical study. Patients were randomly assigned into one of a 2 groups (8 patients each): bone substitute grafting of the intrabony defect, control group (Gr1), intrabony defect osseous wall swaging (OWS) combined xenograft (Gr2). In both groups root surfaces where treated with a neutral 24% EDTA gel and saline irrigation. Clinical and radiographic measurements were reassessed at 6 months after surgery.

Official Title
-----------------
A Novel Approach of Periodontal Osseous Wall Piezosplitting and EDTA Root Surface Etching in Management of Localized Intrabony Defects With Wide Angulation. Controlled Clinical Trial

Conditions
-----------------
Periodontitis

Intervention / Treatment
-----------------
* Procedure: bone swaging


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: good compliance with plaque control instructions following initial therapy teeth involved were all vital with no mobility ; each subject contributed a single predominately 2 or 3-wall intrabony interproximal defect around premolar or molar teeth without furcation involvement; Exclusion Criteria: no systemic diseases which could influence the outcome of therapy; absence of periodontal treatment during the previous year.

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: bone swaging alone<br>xenograft alone | Procedure: bone swaging<br>* osseous wall pedicle was placed to treat the infrabony defect by autogrnous bone<br>|
| Experimental: bone swaging plus EDTA<br>bone swaging with EDTA | Procedure: bone swaging<br>* osseous wall pedicle was placed to treat the infrabony defect by autogrnous bone<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Radiographic evaluation | removing the defect as seen in radiograph defect filling with bone swaging with edta and bone substitute | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical pocket depth | By periodontal prob to measure the clinical parameter | 3month |
Detection of Immune Changes as a Result of Surgical Trauma in Human Subject

Study Overview
=================
Brief Summary
-----------------
Surgical trauma triggers a massive inflammatory response. Over time, both the innate and adaptive branches of the immune system are affected by surgical trauma. The purpose of this study to characterize the cellular and molecular mechanisms immune response to surgical trauma. Additionally, detailed information about patients' recovery profile will be recorded over a period of 6 weeks, with the eventual goal of linking immune responses to recovery profiles.

Official Title
-----------------
Detection of Immune Changes as a Result of Surgical Trauma in Human Subject

Conditions
-----------------
Surgical Trauma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 - 90 Planning to undergo hip surgery Fluent in English Willing and able to sign informed consent and HIPAA authorization Exclusion Criteria: Any systemic disease that might compromise the immune system Diagnosis of cancer within the last 5 years Psychiatric, immunological, and neurological conditions that would interfere with the collection and interpretation of study data Pregnancy Any other conditions that, in the opinion of the investigators, may compromise a participant's safety or the integrity of the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mass cytometry of immune signaling events | The primary molecular outcome is the fold change in phosphorylation of signaling proteins. | Blood samples for mass cytometry will be drawn at baseline, 1 hour post-op, 24 hours post-op, 3 days post-op, and 6 weeks post-op. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Surgical Recovery Scale (SRS) | The surgical recovery scale is a validated questionnaire yielding a numerical score and assessing postoperative recovery. | Data will be collected at baseline, daily through the hospitalization, and every 3 days for 6 weeks. | 
| Western Ontario and McMaster Universities Arthritis Index (WOMAC) | Western Ontario and McMaster Universities Arthritis Index is a validated questionnaires yielding a numerical score and assessing functional status and pain in patients suffering from osteoarthritis of the hip. | Data will be collected at baseline, daily through the hospitalization, and every 3 days for 6 weeks. | 
| Plasma cytokines | The plasma concentration of plasma cytokines and chemokines will be measured with aid of a large protein array. | Blood samples will be drawn at baseline, 1 hour post-op, 24 hours post-op, 3 days post-op, and 6 weeks post-op. |
Optimizing Fidelity to Family-Based Treatment for Adolescent Anorexia Nervosa

Study Overview
=================
Brief Summary
-----------------
This study will use a data base of archived therapy sessions of family therapy for adolescent anorexia nervosa to determine the role of fidelity to treatment and outcome. In addition, it will develop a novel, more efficient way to train therapists in family therapy for adolescent anorexia nervosa and examine if it is feasible to conduct a trial comparing this novel training to standard, more intensive training.

Official Title
-----------------
Optimizing Fidelity to Family-Based Treatment for Adolescent Anorexia Nervosa

Conditions
-----------------
Online Training for Therapists

Intervention / Treatment
-----------------
* Other: Standard FBT training
* Other: Novel FBT training


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: masters or doctoral training in their field (psychology, psychiatry, family therapy). must be licensed have no reports of malpractice or loss of privileges at clinical institution minimum caseload 5 adolescents with AN each year over past 3 years no previous training in FBT computer/web access Exclusion Criteria: Previous FBT training for AN
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Standard training<br>Therapists will receive standard training in FBT. | Other: Standard FBT training<br>* Therapists will receive standard training in Family Based Treatment (FBT)<br>|
| Experimental: Novel training<br>Therapists will receive a novel, more efficient training in FBT | Other: Novel FBT training<br>* Therapists will receive a novel training in Family Based Treatment (FBT)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Feasibility | The primary outcome will be feasibility (e.g., recruitment, attrition, assessment battery, resource costs) to conduct a sufficiently powered comparative study. | end of treatment (approximately 1.5 years after beginning training) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fidelity | Secondary outcomes include exploring differences in therapist fidelity and relationships between fidelity and patient outcomes between these two groups (e.g., fidelity and weight change at session 4). | Session 4, end of training (approximately 1.5 years after beginning training) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
FBT, fidelity, training
Clinical Evaluation of ExoDx Prostate(IntelliScore) in Men Presenting for Initial Prostate Biopsy

Study Overview
=================
Brief Summary
-----------------
The study described here is being conducted to prospectively confirm the performance of the ExoDx Prostate gene expression assay in patients presenting for an initial prostate biopsy and support of CE-marking the test for a European Union Launch.

Official Title
-----------------
Clinical Evaluation of ExoDx™ Prostate(IntelliScore) in Men Presenting for Initial Prostate Biopsy

Conditions
-----------------
Urologic Cancer

Intervention / Treatment
-----------------
* Diagnostic Test: ExoDx Prostate(IntelliScore)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical suspicion for prostate cancer Elevated Prostate-specific Antigen between 2.0-10 ng/ mL Scheduled for a initial prostate biopsy Exclusion Criteria: Clinical symptoms of urinary tract infection (including prostatitis) at the time of enrollment. History of prostate cancer. History of invasive treatments for benign prostatic hypertrophy (BPH) or lower urinary track symptoms within 6 months of study enrollment. Known hepatitis status (all types) and/or HIV documented in patient's medical record. Patients with history of concurrent renal/bladder tumors. Prior MRI used in the decision to biopsy

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
Male

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: ExoDx Prostate(IntelliScore)|The ExoDx Prostate test result supports the biopsy decision process by stratifying patients based on risk for high grade prostate cancer|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation of the ExoDx Prostate test results with the outcome of prostate biopsies in an initial biopsy patient cohort. |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
exosome, ExoDx Prostate
The Study in the Correlation Between the Severity of Post-stroke Fatigue and the Severity of qi Deficiency and Blood Stasis

Study Overview
=================
Brief Summary
-----------------
The purpose of the present study was to investigate the correlation between the severity of fatigue, and the severity of qi deficiency and blood stasis.

Detailed Description
-----------------
According to the reports of department of Health, stroke has been the top three ranking in leading ten major mortality causes. Although fatigue is a common symptom after stroke, but it is easy to neglect due to fatigue is a non-specific symptom. Based on the literature review, fatigue symptom is not only common on post-stroke patient and it also has highly correlation with mortality, prognosis and efficacy of rehabilitation. In Traditional Chinese Medicine recording, Wang Qing-ren suggests that the main etiology of stroke is results from qi stagnation and blood stasis, thereafter, the study about qi deficiency and blood stasis became to the main stream for stroke until now. Therefore, the purpose of the present study was to investigate the correlation between the severity of fatigue, and the severity of qi deficiency and blood stasis.

Official Title
-----------------
The Study in the Correlation Between the Severity of Post-stroke Fatigue and the Severity of qi Deficiency and Blood Stasis in Chinese Medicine.

Conditions
-----------------
Poststroke Fatigue

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Gender: men or women Age:40 80 years old Stroke history at least 3 months Hemorrhage or ischemic stoke Conscious clear and can communicate Brief Fatigue Inventory-Taiwan form score ≥ 4 Sign informed consent Exclusion Criteria: Patient with psychotic diagnosis and can't cooperate with researcher Major disease: chronic obstructive pulmonary disease, heart failure, myocardial infarction, chronic renal failure, liver cirrhosis Pregnant women Breastfeeding women

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| fatigue<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frome Fatigue severity level scale to evaluate fatigue severity score. | When patient visit first time,we complete all the evaluation scale. Total evaluation time is about 20 minutes. And all data will be analyzed one year later. | about 20 minutes |
Post-Poliosyndrome Treated With Intravenous Immunoglobulin (IvIg)

Study Overview
=================
Brief Summary
-----------------
Inflammatory cytokines in the cerebrospinal fluid may contribute to the new muscle weakness, fatigue and pain experienced by patients with post-polio syndrome. Intravenousimmunoglobulin (IvIg) reduces this inflammation. The purpose of this study is to investigate the clinical effect of IvIg in post-polio syndrome.

Detailed Description
-----------------
Post-polio syndrome (PPS) is characterised by new muscle weakness, pain, and fatigue several years after the attack of acute polio. This leads to increased disability, and up to now only supportive therapy is available. Patients with PPS lose more motor neurons than expected and surviving neurons fail to maintain neurogenic supply to enlarged motor units. New data report an increased level of inflammatory cytokines in the cerebrospinal fluid (CSF). Immune modulating therapy like IvIg could be an option and this pilot study is the first to investigate the clinical effect of IvIg in PPS. In addition, levels of cytokines in CSF and serum before and after treatment will be investigated.

Official Title
-----------------
Post-Polio Syndrome Treated With Intravenous Immunoglobulin (IvIg)

Conditions
-----------------
Post-Polio Syndrome

Intervention / Treatment
-----------------
* Drug: IvIg


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Post-polio syndrome diagnosed at Dept of Neurology, Haukeland University Hospital Walking ability - Exclusion Criteria: Other autoimmune disorders Other ongoing autoimmune therapy Severe cardiopulmonary disease IgA deficiency Previous treatment of IvIg Wheelchair dependence

Ages Eligible for Study
-----------------
Minimum Age: 0 Years
Maximum Age: 75 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: IvIg|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain after three months |  |  | 
| Fatigue after 3 months |  |  | 
| Muscle strength after 3 months |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain, Fatigue, Muscle strength after 6 months. Changes in cytokine levels in CSF and serum |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Post-polio syndrome, IvIg